Abbott Laboratories (ABT) - Total Liabilities
Based on the latest financial reports, Abbott Laboratories (ABT) has total liabilities worth $32.92 Billion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Abbott Laboratories long-term investment allocation to see how much of total assets are deployed in long-term investments.
Abbott Laboratories - Total Liabilities Trend (1985–2024)
This chart illustrates how Abbott Laboratories's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ABT total assets.
Abbott Laboratories Competitors by Total Liabilities
The table below lists competitors of Abbott Laboratories ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Toyota Motor Corporation
F:TOMA
|
Germany | €62.35 Trillion |
|
Commonwealth Bank of Australia
AU:CBA
|
Australia | AU$1.37 Trillion |
|
SoftBank Group Corp
F:SFTU
|
Germany | €32.30 Trillion |
|
Reliance Industries Limited
NSE:RELIANCE
|
India | Rs9.88 Trillion |
|
Walt Disney Company
NYSE:DIS
|
USA | $89.91 Billion |
|
SIEMENS AG SP. ADR 1/ 1/2
F:SIEB
|
Germany | €98.11 Billion |
|
COMMONW.BK AUSTR.SP.ADRS
F:CWW0
|
Germany | €1.33 Trillion |
|
PepsiCo Inc
NASDAQ:PEP
|
USA | $89.92 Billion |
Liability Composition Analysis (1985–2024)
This chart breaks down Abbott Laboratories's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Abbott Laboratories to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.52 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Abbott Laboratories's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Abbott Laboratories (1985–2024)
The table below shows the annual total liabilities of Abbott Laboratories from 1985 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $33.51 Billion | -2.54% |
| 2023-12-31 | $34.39 Billion | -8.38% |
| 2022-12-31 | $37.53 Billion | -4.18% |
| 2021-12-31 | $39.17 Billion | -0.94% |
| 2020-12-31 | $39.55 Billion | +8.09% |
| 2019-12-31 | $36.59 Billion | +0.37% |
| 2018-12-31 | $36.45 Billion | -19.27% |
| 2017-12-31 | $45.15 Billion | +41.33% |
| 2016-12-31 | $31.95 Billion | +60.38% |
| 2015-12-31 | $19.92 Billion | +1.45% |
| 2014-12-31 | $19.64 Billion | +11.03% |
| 2013-12-31 | $17.69 Billion | -56.25% |
| 2012-12-31 | $40.42 Billion | +13.07% |
| 2011-12-31 | $35.75 Billion | -3.34% |
| 2010-12-31 | $36.99 Billion | +25.30% |
| 2009-12-31 | $29.52 Billion | +18.36% |
| 2008-12-31 | $24.94 Billion | +13.70% |
| 2007-12-31 | $21.94 Billion | -0.85% |
| 2006-12-31 | $22.12 Billion | +50.24% |
| 2005-12-31 | $14.73 Billion | +1.97% |
| 2004-12-31 | $14.44 Billion | +5.85% |
| 2003-12-31 | $13.64 Billion | +0.36% |
| 2002-12-31 | $13.59 Billion | -4.51% |
| 2001-12-31 | $14.24 Billion | +112.10% |
| 2000-12-31 | $6.71 Billion | -4.70% |
| 1999-12-31 | $7.04 Billion | -6.12% |
| 1998-12-31 | $7.50 Billion | +6.23% |
| 1997-12-31 | $7.06 Billion | +12.01% |
| 1996-12-31 | $6.31 Billion | +25.71% |
| 1995-12-31 | $5.02 Billion | +12.10% |
| 1994-12-31 | $4.47 Billion | +11.48% |
| 1993-12-31 | $4.01 Billion | +11.69% |
| 1992-12-31 | $3.59 Billion | +17.73% |
| 1991-12-31 | $3.05 Billion | +11.82% |
| 1990-12-31 | $2.73 Billion | +28.44% |
| 1989-12-31 | $2.13 Billion | -9.97% |
| 1988-12-31 | $2.36 Billion | +2.98% |
| 1987-12-31 | $2.29 Billion | +9.85% |
| 1986-12-31 | $2.09 Billion | +30.61% |
| 1985-12-31 | $1.60 Billion | -- |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary s… Read more